Inactive Instrument

Profound Medical Corp Stock Toronto S.E.

Equities

PRN

CA74319B1067

Advanced Medical Equipment & Technology

End-of-day quote Toronto S.E.
- CAD - Intraday chart for Profound Medical Corp
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 15.95M 11.67M Sales 2025 * 43.69M 31.98M Capitalization 246M 180M
Net income 2024 * -38M -27.81M Net income 2025 * -30M -21.96M EV / Sales 2024 * 14.5 x
Net cash position 2024 * 13.74M 10.05M Net Debt 2025 * 41.34M 30.25M EV / Sales 2025 * 6.57 x
P/E ratio 2024 *
-6.45 x
P/E ratio 2025 *
-7.16 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.29%
More Fundamentals * Assessed data
Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating MT
Stifel Adjusts Price Target on Profound Medical to $9 From $11, Keeps Hold Rating MT
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Profound Medical Corp., Q4 2023 Earnings Call, Mar 07, 2024
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer MT
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share MT
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms DJ
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure MT
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers CI
Profound Medical Brief: Entering Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure MT
Profound Medical Up 1.9% In US After Hours As Announces Non-Brokered Private Placement MT
Profound Medical Corp. announced that it expects to receive $2.937503 million in funding CI
Profound Medical Brief: Adds Top priorities for 2024 will be to further increase Its TULSA-PRO installed base, support increased system utilization, complete its ongoing Level 1 CAPTAIN trial MT
More news
Managers TitleAgeSince
Chief Executive Officer 69 15-06-03
Director of Finance/CFO 56 15-06-30
Chief Operating Officer 42 11-07-06
Members of the board TitleAgeSince
Director/Board Member 77 18-06-13
Director/Board Member 67 18-06-13
Director/Board Member - 21-03-02
More insiders
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW